Fluad H5N1 Pandemic Influenza Vaccine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Prophylaxis of Avian Influenza Vaccine

Drug Information

Target Indication

Prophylaxis of Avian Influenza Vaccine

Clinical Trial

Last updated: 1/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA11/15/2024

Fluad

Prophylaxis of influenza in adults 50 years of age and older. Fluad should be used in accordance with official recommendations.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Neovascular Age-related Macular Degeneration

Renal Interstitial Fibrosis

Pathological Myopia

Non-Small Cell Lung Cancer

Prostatic Neoplasms

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts